Finally, VEGFR2, MAGE-A1, MAGE-A4, PSCA, AXL, Claudin 18.2, TGFB, CD22, ROR1, OX40, DLL3, MSLN, and EpCAM are being targeted in CAR-T cell clinical trials for lung cancer. Here, MSLN is linked to lung carcinoma.